Monocarboxylate transporter 8 (MCT8) facilitates cellular uptake and efflux of thyroid hormone (TH). Mutations in MCT8 result in severe intellectual and motor disability known as the Allan-HerndonDudley syndrome (AHDS). Previous studies have provided valuable insights into the putative mechanism of substrate binding in the inward-open conformation, required for TH efflux. The current study aims to delineate the mechanism of substrate binding in the outward-open conformation, required for TH uptake. Extensive chemical modification and site-directed mutagenesis studies were used to guide protein homology modeling of MCT8 in the outward-open conformation. Arg271 and Arg445 were modified by phenylglyoxal, which was partially prevented in the presence of substrate. Substrate docking in our outward-open model suggested an important role for His192 and Arg445 in substrate binding. Interestingly, mutations affecting these residues have been identified in patients who have AHDS. In addition, our outward-open model predicted the location of Phe189, Met227, Phe279, Gly282, Phe287, and Phe501 at the substrate-binding center, and their Ala substitution differentially affected the apparent Vmax and Km of T3 transport, with F189A, F279A, and F287A showing the highest impact. Thus, here we present an MCT8 homology model in the outward-open conformation, which supports the important role of His192 and Arg445 in substrate docking and identifies critical residues at the putative substrate-binding center. Our findings provide insights into MCT8 structure and function, which add to our understanding of the pathogenic mechanism of mutations found in patients who have AHDS and can be used to screen for novel substrates and inhibitors. (Endocrinology 158: 3292-3306, 2017) T hyroid hormone (TH) requires TH transporter proteins to allow its cellular entry, action, and metabolism (1, 2). Monocarboxylate transporter 8 (MCT8) is the most specific TH transporter known to date and facilitates the transport of 3,3 0 ,5,5 0 -tetraiodo-L-thyronine (T4), 3,3 0 ,5-triiodo-L-thyronine (T3), and to a lesser extent 3,3 0 ,5 0 -triiodo-L-thyronine and 3,3 0 -diiodo-L-thyronine (3, 4). Entry of TH into the brain appears highly MCT8 dependent, indicating an important physiological role of MCT8 in TH homeostasis in the brain (5, 6). Mutations in the MCT8 (SLC16A2) gene result in the Allan-Herndon-Dudley syndrome (AHDS), which is characterized by severe intellectual and motor disability and peripheral thyrotoxicosis (7, 8) . Different types of MCT8 mutations have been identified in patients who have AHDS (7, 8) . Although most mutations result in a
T hyroid hormone (TH) requires TH transporter proteins to allow its cellular entry, action, and metabolism (1, 2) . Monocarboxylate transporter 8 (MCT8) is the most specific TH transporter known to date and facilitates the transport of 3,3 0 ,5,5 0 -tetraiodo-L-thyronine (T4), 3, 3 0 ,5-triiodo-L-thyronine (T3), and to a lesser extent 3,3 0 ,5 0 -triiodo-L-thyronine and 3,3 0 -diiodo-L-thyronine (3, 4) . Entry of TH into the brain appears highly MCT8 dependent, indicating an important physiological role of MCT8 in TH homeostasis in the brain (5, 6) . Mutations in the MCT8 (SLC16A2) gene result in the Allan-Herndon-Dudley syndrome (AHDS), which is characterized by severe intellectual and motor disability and peripheral thyrotoxicosis (7, 8) . Different types of MCT8 mutations have been identified in patients who have AHDS (7, 8) . Although most mutations result in a (near-) complete inactivation of TH transport capacity, the molecular pathogenic mechanism varies (7, 8) . Several mutations have been found to interfere with protein expression and subcellular localization (truncating mutations, insertions/deletions, and missense mutations affecting Pro and Gly residues), whereas others specifically interfere with substrate translocation (mostly missense mutations) (9) (10) (11) (12) (13) (14) . Because protein structure and function are intimately related, detailed insights into the MCT8 structure are required to better understand its physiological substrate translocation mechanism and the impact of different mutations. However, crystal or nuclear magnetic resonance structures of MCT8 are currently lacking.
Because crystallization of integrated membrane proteins is cumbersome, protein homology modeling is an effective alternative if a suitable template structure is available. MCT8 belongs to the major facilitator superfamily (MFS), which have been suggested to share a common structural organization, even in the absence of apparent sequence similarity (15) . Furthermore, all MFS proteins seem to use a similar substrate translocation mechanism according to the rocker-switch model, in which the binding of a substrate molecule to a substratebinding center initiates the transition from the outwardopen to the inward-open conformation (uptake) or vice versa (efflux) (15) . Therefore, crystal structures of other MFS members could serve as suitable templates for MCT8 modeling.
Indeed, an MCT8 homology model in the inwardopen conformation based on the Escherichia coli glycerol-3-phosphate transporter [GlpT; Protein Data Bank (PDB) no. 1PW4] has been previously reported (4) . This model complies to several important in vitro studies that suggested a close structural proximity of Arg445, located in transmembrane domain (TMD) 8, and Asp498, located in TMD10, allowing the formation of a hydrogen bond between these residues, and a channel-facing orientation of His192 (TMD1) (4, 10, 11) . Based on these findings, it was postulated that His192 and Arg445 form a His-Arg clamp, facilitating the docking of TH at the substrate-binding center in the inward-open conformation (4, 10) . Moreover, it predicted most missense mutations, identified in patients who have AHDS, within TMDs or at helix-loop transitions, but not in extracellular loops (ECLs) or intracellular loops (ICLs) (4, 16) . However, this model did not accommodate the accessible position of Cys497 as suggested by in vitro chemical modification studies with p-chloromercuribenzene sulfonate (pCMBS) (17) . Moreover, the homology model in inward-open conformation mainly provides insights into substrate recruitment and docking from the intracellular side during TH efflux. For a better understanding of the full transport cycle, additional MCT8 models in other conformations are thus required. Specifically, a homology model in the outward-open conformation is warranted for a more detailed understanding into transporter structure and substrate docking from the extracellular side during TH uptake.
Therefore, we used chemical modification and sitedirected mutagenesis studies, to guide protein homology modeling of MCT8 in the outward-open conformation. In addition to our previous chemical modification and mutational studies, we here present in vitro evidence supporting the localization of Arg445 at the substratebinding center. Subsequent substrate docking and molecular dynamic simulation studies of our structure model indeed support the presence of a direct interaction of His192 and Arg445 with TH at the substrate-binding center. Finally, our findings suggest that other residues predicted at the substrate-binding center may be of differential importance for substrate docking and translocation, depending on their position and orientation toward the substrate. Our findings provide insights into MCT8 structure and function and contribute to a better understanding of the MCT8 substrate translocation cycle and the impact of pathogenic mutations found in patients who have AHDS. Moreover, our model can be used to screen for novel MCT8 substrates and inhibitors.
Experimental Procedures

Materials
Unlabeled iodothyronine derivatives, bovine serum albumin (BSA), D-glucose, 2-hydroxy-5-nitrobenzyl bromide (HNBB), N-acetyl-imidazole (NAI), phenylglyoxal (PG), and phenylmethanesulfonyl fluoride (PMSF) were obtained from SigmaAldrich (Zwijndrecht, The Netherlands). ]T 4 were synthesized as described previously (18) . Transfection reagent X-tremeGENE 9 from Roche (Almere, The Netherlands), sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis gels from Thermo Fisher (Breda, The Netherlands), nitrocellulose membrane from GE Healthcare (Eindhoven, The Netherlands). Antibody information is summarized in Supplemental Table 1 . Vectashield H-1200 containing 4 0 ,6-diamidino-2-phenylindole was obtained from Brunschwig (Amsterdam, The Netherlands).
sequences are listed in Supplemental Table 2 ). The position of the mutations is indicated using the NM_006517.3 reference sequence and uses +1 as the A of the ATG translation initiation codon of the long MCT8 isoform, with the initiation codon as codon 1. DNA sequencing confirmed the presence of the introduced mutations and the absence of unintended mutations.
Cell culture and transfection
COS-1 and JEG-3 cells were cultured in 6-or 24-well dishes (Corning, Schiphol, The Netherlands) in Dulbecco's modified Eagle medium/F12 medium (Invitrogen, Breda, The Netherlands), containing 9% heat-inactivated fetal bovine serum (Invitrogen), 2% penicillin/streptomycin (Roche, Woerden, The Netherlands), and 100 nM sodium selenite (Sigma-Aldrich). Cells were transfected at 70% confluency, and all experiments were carried out 48 hours after transfection. For TH uptake experiments, cells were seeded in 24-well dishes and transiently cotransfected in duplicate with 50 ng wild-type (WT) or mutant MCT8, 50 ng pcDNA3 empty vector (EV), and either 100 ng pSG5.CRYM or pcDNA3 EV. For Western blotting, cells were seeded in six-well dishes and transiently transfected with 500 ng WT or mutant MCT8 or pcDNA3 EV. For immunocytochemistry, JEG-3 cells were cultured in 24-well dishes on 10-mm glass coverslips coated with poly-D-lysine (Sigma-Aldrich) and transiently transfected with 250 ng of WT or mutant pcDNA3-hMCT8. We previously described the absence of significant differences in transfection efficiency between MCT8 WT and mutants (21) .
TH uptake
TH uptake experiments were performed according to previously described methods (11) . If mentioned, cells were first preincubated for 15 minutes at room temperature (RT) in incubation medium [Dulbecco phosphate-buffered saline (D-PBS) and 0.1% D-Glucose] containing the indicated chemical modifier or vehicle without or with 10 mM T3, washed twice for 1 minute in incubation medium containing 1% BSA, and once for 1 minute in incubation medium without BSA, prior to the uptake assay. Uptake studies were performed for the indicated times at 37°C using incubation medium containing 0.1% BSA, 1 nM unlabeled T3 or T4, and 5 
Cell viability assay and measurement of protein content
To exclude toxic effects of chemical modification reagents, cells were cultured in 96-well plates (cell viability) or 24 wellplates (protein measurement). After 72 hours, cells were incubated for 10 minutes with different concentrations of the chemical modification reagents as described above, washed once with phosphate-buffered saline (PBS) containing 0.1% BSA, and twice with PBS without BSA. The cells cultured in the 24-well plates were lysed in 0.1 M NaOH to measure total protein levels using the Bradford assay (BIO-RAD, Veenendaal, The Netherlands). The cells cultured in the 96-well plates were incubated for 3 hours at 37°C with 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in Dulbecco's modified Eagle medium-F12. After aspiration of the medium, cells were solubilized in dimethyl sulfoxide, and the absorbance of converted dye was measured at a 560 nm using a Victor 2 multilabel plate reader (Perkin Elmer, Rotterdam, The Netherlands).
Cell surface biotinylation
For cell surface biotinylation assays, COS-1 cells were cultured on 10-cm dishes and transiently transfected with 1500 ng WT or mutant MCT8 at 60% confluence. After 48 hours, cells were washed three times with ice-cold D-PBS containing 1 mM MgCl 2 and 0.1 mM CaCl 2 [Dulbecco phosphate-buffered saline containing 2 mM MgCl 2 and 0.1 mM CaCl 2 (D-PBS-CM)]. Surface proteins were subsequently labeled for 30 minutes at 4°C with 1 mg/mL EZ-Link Sulfo-NHS-Biotin (Thermo Fisher) in D-PBS-CM with gentle agitation. Free biotin was quenched by washing cells once with quenching buffer (D-PBS-CM, 100 mM glycine, pH 7.4) and an additional incubation with quenching buffer for 15 minutes at 4°C with gentle agitation. Cells were subsequently washed twice with ice-cold D-PBS-CM and lysed with immunoprecipitation buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100) containing protease inhibitor cocktail (Roche). Lysates were briefly sonicated and then clarified by centrifugation (5 minutes at 10,000g and 4°C). An aliquot of the clarified sample was stored as input control (5% of total volume). Biotin-labeled surface proteins were then isolated by incubating lysates overnight at 4°C with 50 mL prewashed NeutrAvidin agarose beads (Thermo Fisher) under gentle rotation. Subsequently, beads were washed three times with immunoprecipitation buffer-containing protease inhibitors, and bound proteins were eluted by incubating the beads for 10 minutes at 70°C with 20 mL 43 SDS sample buffer. The eluate was analyzed by Western blotting as described later.
Western blotting
Western blots were carried out as previously described, with some modifications (11) . After a brief wash with PBS, cells were harvested in lysis buffer containing 100 mM Na-phosphate and 2 mM EDTA and protease inhibitor cocktail (Roche), and sonicated for 10 seconds. After 10 minutes' incubation at 70°C in sample loading buffer containing SDS and dithiothreitol, samples were loaded on a 10% precast SDS-polyacrylamide gel electrophoresis gel (Thermo Fisher). After blotting, membranes were blocked for 2 hours in PBS containing 0.1% Tween and 5% milk and probed with MCT8 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies (as a loading control) overnight at 4°C (see Supplemental Table 1 for details). MCT8 and GAPDH were visualized by Odyssey using IRDye680 goat anti-rabbit and IRDye800 goat anti-mouse (LI-COR, Leusden, The Netherlands) secondary antibodies, respectively.
Immunocytochemistry
Two days after transfection, cells were fixed for 20 minutes at 37°C with 4% paraformaldehyde in D-PBS and permeabilized for 5 minutes at RT with 0.2% Triton X-100 in PBS. Samples were washed for 1 hour at RT in D-PBS containing 1% BSA and incubated overnight at 4°C with MCT8 and ZO-1 antibodies (Supplemental Table 1 ). Primary antibodies were visualized with goat anti-rabbit Alexa Fluor 488 and goat antimouse Alexa 633 (Supplemental Table 1 ), respectively. Coverslips were mounted on glass slides using Vectashield H-1200 containing 4 0 ,6-diamidino-2-phenylindole (Brunschwig). Samples were examined on a Zeiss Meta 510 microscope using Zeiss LSM software (Zeiss NL, Sliedrecht, The Netherlands). A Plan Neofluar 4031.3 oil objective and lasers of 405, 488, and 633 nm wavelength were used. Images were prepared using ImageJ software.
Protein homology modeling
The automatic homology modeling algorithm implemented in YASARA Structure Software (YASARA Biosciences GmbH, Vienna, Austria) was used to construct different MCT8 homology models in the outward-open conformation (22, 23) . In summary, the sequence of MCT8 was PSI-BLASTed (24) with three iterations against the UniRef90 database to build a position-specific scoring matrix (PSSM) with related sequences. These included the MCT8 and MCT10 sequences from different species. The PSSM was used to search the PDB database for potential modeling templates. The putative templates were automatically ranked based on the alignment score and their structural quality according to WHAT_CHECK (25) obtained from the PDBFinder2 database (26) . For the top five most suitable templates, five putative alignments with the MCT8 target sequence were generated per template using a secondary structure prediction and PSSM of the MCT8 target sequence (24, (27) (28) (29) and the sequence profile of the templates, derived from YASARA's Profiles from Sequence-and Structurally Related Proteins database and additional UniRef90 sequences, yielding a multiple sequence alignment that is anchored on an accurate structural alignment (28, 30) . Next, for each alignment an initial rotamer solution was generated. If templates contain ligands, these molecules were considered in the homology modeling procedure. Loops were modeled by scanning a nonredundant subset of the PDB database (.10,000 structures) for fragments with matching anchor points, a minimal number of bumps, and maximum sequence similarity. Side chains were added with YASARA's implementation of Side Chains With Rotamer Library (23, 31) , side-chain rotamers were fine-tuned, and the hydrogen-bonding network was optimized. Finally, each model was subjected to a short energy minimization step with the YASARA2 force field as described previously (23) . Because this is only a minimization, the water molecules mainly serve to screen for electrostatic interactions and it therefore does not matter that the MCT8 protein is normally not fully solvated.
In total 25 models were generated, based on five different template PDBs (Supplemental Table 3 ). All models were manually inspected and challenged by the obtained in vitro data as summarized in Supplemental Table 4 . Based on the conformational state (outward-open), model quality and compatibility with as many as possible in vitro findings, the E. coli L-fucose-proton symporter, (FucP; PDB no. 3O7P) in the outward-open conformation was selected as the most suitable template (Psi-BLAST alignment score 77, coverage 67%, resolution 3.2Å, z score crystal structure: 0.425). The alignment was slightly adapted at TMD10 to render Cys497 accessible for pCMBS modification. Furthermore, the secondary structure of ECL3 was slightly adjusted to allow a better fit with the presumed a-helical structure of TMD5 (32) . The final alignment is provided in Supplemental Fig. 1 . The final model was minimized without further constraints using the YASARA 2 force field. The final model was validated with WHAT_CHECK (25) and yielded an average quality z score of 21.29 (range: , 25, terrible to . 0, optimal), which is a satisfactory quality level.
Substrate docking and molecular dynamic simulations
After visualization of the molecular surface, a T3 molecule was manually introduced into the substrate pore in proximity of the proposed substrate-binding center in the outward-open conformation. Optimization of the protein structure and, if indicated, substrate position was performed using molecular dynamic simulations. For this purpose, the MCT8 protein model was first introduced into a membrane environment while keeping the substrate pore solvated with water (described in detail in Supplemental Materials and Methods). After an initial equilibration step of 250 ps, further molecular dynamic simulations were carried out in an AMBER 14 force field with periodic boundaries (23, 33) . Snapshots of the substrate-binding pore were taken after 2 and 4 ns. Next, several residues with side-chains within 5Å of the T3 molecule were selected for mutagenesis studies and further functional evaluation. All images were created using YASARA Structure and Pov-Ray v3.6 software (www.povray.org).
Statistical analysis
All uptake results are expressed as means 6 standard error of the mean of at least two to six separate experiments in duplicate. P values ,0.05 were regarded as statistically significant. Statistical significance was determined as indicated in the legends of the corresponding figures. Km and Vmax values were calculated using Michaelis-Menten equation implemented in GraphPad Prism, version 6 (GraphPad, La Jolla, CA). Linear regression was used to generate an Eadie-Hofstee plot from the kinetic data.
Results
To identify accessible residues within MCT8 that are putatively important for MCT8 transport function, we first studied the effect of selective amino acid modifying reagents on MCT8-mediated T3 transport. We have previously shown that preincubation with His-reactive diethylpyrocarbonate (DEPC) and Cys-reactive pCMBS resulted in an inhibition of subsequent MCT8-mediated TH transport (11, 17) . We now preincubated COS-1 cells coexpressing WT MCT8 and the intracellular TH binding protein CRYM with increasing concentrations of NAI, which targets accessible Tyr residues, PMSF, which targets accessible Ser residues, HNBB, which targets accessible Trp residues, and PG, which targets accessible Arg residues. Preincubation with increasing concentrations of NAI or PMSF did not result in significant impairment of MCT8-mediated T3 uptake [ Fig. 1 (a) and 1(b)], suggesting that no Ser or Tyr residues are modified, or that modification of potentially available Tyr or Ser residues does not interfere with substrate translocation. In contrast, preincubation with increasing concentrations of HNBB and PG resulted in a dose-dependent decrease in MCT8-mediated T3 uptake [ Fig. 1(c) and 1(d) ]. No significant toxic effects were observed for the concentrations of HNBB and PG used, and the highest concentrations of PG and HNBB used in these studies did not affect MCT8 protein expression levels, or cell surface translocation (Supplemental Fig. 2(a-c) ]. Similar results were obtained in JEG-3 cells (data not shown).
To exclude that the observed inhibitory effect of HNBB was mediated by modification of CRYM, we confirmed these effects of HNBB on MCT8-mediated T3 uptake in the absence of CRYM [ Fig. 2(a) ]. To identify putative target residues for HNBB modification, a mutational screen of Trp residues located in the predicted ECLs and TMDs was performed. Trp175, Trp183, Trp219, Trp398, or Trp431 were substituted with Phe, maintaining the large aromatic group and hydrophobic properties of the side-chain, or with Ala, reducing the side-chain size. Supplemental Table 5 summarizes the predicted locations within the protein and conservation of these Trp residues across species and MCT family members. Upon expression in COS-1 cells, the W175A, W219F, and W219A mutants showed a small but significant reduction of MCT8-mediated T3 uptake compared with WT [ Fig. 2(b) ]. Similar results were observed for T4 uptake [Supplemental Fig. 3(a) ]. All mutants were detected as monomer and homo-dimer [Supplemental Fig. 3(b) ]. None of the Trp-mutants displayed reduced HNBB sensitivity [ Fig. 2(b) ]. Indeed, when HNBB was tested at pH 6, where HNBB has the highest specificity for Trp residues, the inhibitory effects largely disappeared [ Fig. 2(a) ]. Taken together, these findings suggest that the main inhibitory effect of HNBB results from off-target modifications (34) .
To exclude that the observed inhibitory effect of PG was mediated by modification of CRYM, we first confirmed that these effects of PG on MCT8-mediated T3 uptake also occurred in the absence of CRYM [ Fig. 3(a) ]. To identify the putative target(s) for PG modification, we substituted Arg271, Arg325, Arg445, Arg482, or Arg544, all predicted to be located within ECLs or TMDs, with either Lys, maintaining the positive charge, or with Ala, resulting in a loss of positive charge and reduction of side-chain size. Supplemental Table 5 summarizes the predicted locations within the protein and conservation of these Arg residues across species and the MCT family. The T3 uptake by the R271A, R445K, R445A, and R544K mutants was significantly reduced [ Fig. 3(b) ]. Similar results were observed for T4 uptake [Supplemental Fig. 3(c) ]. All mutants were detected as monomer and homo-dimer [Supplemental Fig. 3(d) ]. All mutants showed a significant reduction in T3 and T4 uptake capacity after preincubation with 50 mM PG, except for the R445A mutant [ Fig. 3(b) ; Supplemental Fig. 3(c) ]. Although the R271A mutant was still sensitive to PG modification, the degree of inhibition of subsequent T3 uptake was significantly lower compared with WT MCT8. None of the Arg to Lys mutants showed a reduction in PG sensitivity, which could be the result of lysine modification by PG (34) . Taken together, these findings suggest that Arg445 and Arg271 are targets for PG modification. Next, we studied whether the inhibiting effect of PG could be prevented in the presence of 10 mM T3. Preincubation with T3 alone reduced subsequent [ 125 I]T3 uptake by about 20% [ Fig. 3(c) ]. Preincubation with 50 mM PG resulted in a 50% reduction of subsequent T3 uptake compared with control cells. This effect was partially prevented in the presence of T3 (Fig. 3(c) ]. These findings suggest that the presence of substrate partially protects against modification of Arg445 and/or Arg271 by PG, which may indicate that the side-chain of at least one of these residues faces the substrate channel.
Next, different MCT8 homology models in the outward-open conformation were generated based on the crystal structure of the FucP (PDB no.3O7P and 3O7Q) (35) using the homology modeling tool of YASARA Structure (see Methods and Supplemental Materials and Methods sections and Supplemental Table 3 for details). The model that best accommodated the current and previously reported in vitro data (Supplemental Table 4 ) Fig. 4(a-d) ]. The putative TMDs are indicated in the legend of Fig. 4(a) and are mostly similar to previous reports (4, 36) . All TMDs have a predominant a-helical organization, whereas the loops mostly consist of random coils or turns. The a-helical structure at the end of the large ICL3 linking TMD6 and TMD7 is an exception to this observation, a well-described phenomenon in MFS proteins including GlpT and FucP (35, 37) . In line with most crystallized MFS transporters, TMD4 shows a less rigid a-helical structure, allowing greater helical flexibility to maximize substrate interactions (15) . Of note, also the MFS signature sequence (DRXXXR) defining the two ends of ICL1 is present in MCT8 (DRLGCR) and properly located in our model (Supplemental Fig. 1 ). Sequence identity (13.2%) and similarity (29.5%) to the FucP template (PDB no. 3O7P) are depicted in Fig.  4(e) , and residue properties in Fig. 4 (f) and 4(g). Importantly, no charged and only few polar residues were found to face the lipid bilayer. Together, these observations re-enforce the accuracy of our model.
After embedding the MCT8 protein model in a lipid bilayer (see Supplemental Materials and Methods) and subsequent molecular dynamic simulations for 4 ns, all side-chains of residues that have been assessed in the present and previously reported chemical modification studies were localized in the model [ Fig. 5(a) ; Supplemental Fig. 4 ]. In line with these studies, Cys481 (ECL5), Cys497 (TMD10), Arg271 (ECL2), Arg445 (TMD8), and His192 (TMD1) are indeed predicted at accessible locations, allowing chemical modification [ Fig. 5(a) ; Supplemental Fig. 4 ]. The localization of Cys497, Arg445, and His192 at the substrate pore is in line with the observed protective effect of substrate on these modifications (10, 11) . Moreover, the Asp498 residue is located in close proximity of Arg445, allowing interactions Figure 2 . (a) T3 uptake by COS-1 cells transfected with MCT8 in the absence of CRYM in 5 minutes at 37°C after preincubation for 10 minutes in the presence of 10 mM HNBB at indicated pH level, and (b) T3 uptake by COS-1 cells coexpressing WT or mutant MCT8 and CRYM after preincubation in the presence or absence of 10 mM HNBB for 10 minutes. All values are corrected for background T3 uptake levels observed in COS-1 cells transfected with pcDNA3 EV, preincubated under identical conditions. T3 uptake levels are expressed relative to MCT8-mediated T3 uptake levels after preincubation in D-PBS without HNBB. Results are presented as means 6 standard error of the mean (n = 3). Statistical significance was tested using two-way analysis of variance followed by Bonferroni posttests. Statistically significant differences are indicated with an asterisk (*). (10). Importantly, all other Cys, Arg, His, and Trp residues were found at positions that are inaccessible for chemical modification (in TMDs but not facing the substrate pore or in ICLs) or at positions where chemical modification is not likely to interfere with TH transport (e.g., in ECLs).
Next, we located residues that are affected by missense mutations in patients who have AHDS of which also the Ala substitutions have been shown to be detrimental for MCT8 function (His192, Arg445, Asp498) in Fig. 5(b)  (10, 11) . Indeed, the side-chains of these residues are all oriented toward the substrate pore. We have previously found that Ala substitution of Ser290, found to be mutated to Phe in a patient with AHDS, did not affect TH transport capacity, suggesting a less important role of the native Ser residue (14) . Our model suggests that the sidechain of this residue is orientated toward TMDs 1, 3, and 6, compatible with the less important functional role of Ser290 itself. In this case, the introduction of the much larger Phe residue is more likely to be pathogenic caused by steric interference with residues located in the surrounding TMDs [ Fig. 5(b) ].
Finally, we focused on the characterization of the substrate-binding center. By modeling of the molecular surface of the MCT8 protein, a central substrate pore was observed [ Fig. 6(a) ]. Hydrophobic residues in the middle and polar/charged residues at the bottom primarily flank this substrate pore [ Fig. 6(a) ]. Two basic residues (His192, Arg445) and one acidic residue (Asp498) were located at the bottom end, which is presumed to be the substrate-binding center. The distance between His192 and Arg445 is about 15Å, which fits with the size of a TH molecule. We next modeled a T3 molecule at the substrate-binding center and highlighted the molecular surface of residue side-chains that are located within 5Å [ Fig. 6(b) ]. Indeed, the T3 molecule exactly fits between green; C-terminus: red). Due to low structural and sequence homology with the template, the large intracellular N-terminus and part of the C-terminus are lacking. The MCT8 protein consists of two near symmetrical parts, each consisting of six transmembrane helices, interconnected by a large ICL between TMD6 and 7. The predicted TMD spans are as follows TMD1: Gln167-Glu204, TMD2: Phe215-Phe238, TMD3: Ile246-Phe264, TMD4: Leu270-His296, TMD5: Arg301-Gly328, TMD6: Phe337-Thr353, TMD7: Met387-Leu416, TMD8 Lys428-Pro456, TMD9: Leu458-Met477, TMD10: Asp483-Phe510, TMD11: Met516-Asn545, and TMD12: Val552-Asp585. The predicted TMD spans show high coincidence with previously reported predictions of MCT8 TMDs (4, 35) . The secondary structure of the loops connecting the TMDs is difficult to predict with great certainty, but mostly consists of random coiled coils or turns, which allow greater flexibility. (d) The N-terminal half of the protein (residues 162-359: green) shows great structural similarities to the C-terminal half of the protein (residues 387-582: blue) and can almost be superimposed. Identical (green) and similar (orange) residues between MCT8 and the modeling template FucP are depicted in (e). Amino acid properties are depicted in (f) from the front side and (g) from the back side. In blue: positively charged residues (Arg, Lys, His), in red: negatively charged residues (Asp, Glu), in gray: hydrophobic residues, in light blue: polar residues containing a hydroxyl group (Ser, Thr, Tyr), and in green: the polar amides (Asn, Gln). Fig. 5(a) ], whereas in the absence of substrate, the g-COOH group of Asp498 could also interact with a v-NH2 group of Arg445 [Supplemental Fig. 5(b) ]. Although molecular dynamic simulations have limitations when performed on homology models, these predictions are consistent with the hypothesis that the presence of substrate can modify interhelical interactions between Arg445 (TMD8) and Asp498 (TMD10).
Subsequently, we sought to test the accuracy of our homology model by predicting relevant residues in the substrate-binding center with subsequent functional assays. The following six residues were located within 5Å distance from the T3 molecule: Phe189 (TMD1), Met227 (TMD2), Phe279 (TMD4), Gly282 (TMD4), Phe287 (TMD4), and Phe501 (TMD10) [ Fig. 6(c) ]. The aromatic side chain of Phe279 parallels that of His192, together forming a cavity in which the phenolic ring of TH perfectly fits. Both Phe189 and Gly282 form the bottom of this cavity. Phe287 forms the bottom of the substrate-binding center and faces the b-methylene group and tyrosyl ring of the T3 molecule. The side-chains of Met227 and Phe501 predominantly point toward the tyrosyl ring and b-methylene group of T3, respectively. To explore the importance of these relatively bulky Phe and Met side-chains in substrate translocation, we substituted these residues with the smaller Ala residue. Moreover, Gly282 was substituted with Ala to increase the size of the side-chain. Interestingly, we have previously described the inactivating effect of the G282C mutation, which was identified in a patient with AHDS (13) .
Upon transfection in COS-1 cells, total protein expression levels and cell surface expression levels of the For clarity reasons, the lipid bilayer is not depicted in this figure, but can be found in Supplemental Fig. 3 . Images are generated using YASARA and PovRay imaging software. (b) Residues that have been found to be mutated in patients who have AHDS of which both the patient mutation and its Ala substitution have been tested. In red, both patient and Ala substitution strongly reduced MCT8-mediated TH transport; and in green, Ala substation was fully functional.
F189A, M227A, F287A, and F501A mutants were similar to WT MCT8 [ Fig. 7(a) and 7(b) ]. In contrast, both F279A and G282A mutants displayed reduced total and cell surface expression levels compared with WT MCT8 [ Fig. 7(a) and 7(b) ]. Both mutants also showed lower expression levels compared with WT MCT8 in total lysates derived from JEG-3 cells [ Fig. 7(c) ]. Nevertheless, all mutants were still detected at the cell membrane in JEG-3 cells (Supplemental Fig. 6 ).
In COS-1 cells, the F279A and F287A mutants showed the strongest decrease in TH uptake in the presence of CRYM [ Fig. 7(d) ]. Interestingly, T4 uptake was even more affected by the F287A mutation than T3 uptake. The F189A mutation also significantly reduced T3 uptake, whereas T4 uptake was less affected. The M227A mutant showed slightly higher T3 and T4 accumulation compared with WT [ Fig. 7(d) ]. The G282A and F501A mutations did not affect TH uptake at these low (1 nM) substrate concentrations. Although a similar pattern was observed in JEG-3 cells [ Fig. 7(e) ], all mutations had a somewhat greater effect compared with COS-1 cells, in particular the F279A and G282A mutants. This discrepancy is a common observation (12, 38) , and may be related to the lower protein expression levels in transiently transfected JEG-3 cells, perhaps reflecting a limited capacity to process overexpressed proteins. Hence, mutations that (also) affect protein stability or trafficking often display stronger impact on MCT8 transport function in JEG-3 cells.
Finally, we evaluated the impact of all mutations on T3 transport kinetics. All mutations resulted in a decrease of apparent Vmax of T3 transport, most predominantly for the F189A, F279A, and F287A substitutions [ Fig. 8(a) and 8(b); Supplemental Table 6 ]. Moreover, the M227A, F279A, F287A, and F501A substitutions resulted in a significant reduction of apparent Km, which may be consistent with an altered mode of substrate binding [ Fig.  8(b) ; Supplemental Table 6 ]. Upon normalization for cell surface protein expression levels, the Vmax of the F279A and G282A mutant did not significantly differ from WT, suggesting that the decrease in Vmax of these substituents may be predominantly driven by a reduction of cell surface expression levels (Supplemental Table 6 ). Interestingly, after correction for cell surface expression levels, the transport efficiency (as indicated by the Vmax/Km ratio) of the F279A and G282A mutants significantly increased over WT, which suggests that although both mutations interfere with cell membrane expression they may increase the intrinsic transport activity of MCT8. In contrast, the F189A and F287A mutants significantly reduced transport efficiency as indicated by the reduction in the Vmax/Km ratio [ Fig.  8(b) ; Supplemental Table 6 ].
Discussion
In the current study, we provide insights into the protein structure and substrate docking mechanism of MCT8 in the outward-open conformation. Our current studies identified Arg271 and Arg445 as accessible residues. These and previously published in vitro findings (10, 11, 17) were used to guide the construction of an MCT8 homology model in outward-open conformation. In line with these studies, our model suggested that Arg445 (TMD8) and His192 (TMD1) directly interact with T3 at the substrate-binding center of MCT8 in the outward-open conformation. Moreover, we here demonstrated that other residues predicted at the substrate-binding center have varying importance for substrate translocation, depending on their relative orientation toward the substrate.
Extensive in vitro analyses were done to gather structural information to guide the homology modeling procedure. In addition to the previously identified The total lysates in COS-1 cells comprise the 5% input sample of the cell surface biotinylation assay of which the biotinylated fraction is presented in (b). MCT8 detection was performed with the N-terminal MCT8 antibody (3353) and visualized with IRDye680 goat anti-rabbit secondary antibody. GAPDH was used as loading control. Bands of approximately 55 kDa, representing the MCT8 monomer (arrow), and a second band around 110 kDa, representing the MCT8 homodimer (arrowhead), were observed in cells transfected with WT or mutant MCT8 constructs. MCT8 and GADPH expression levels were quantified by densitometry using ImageJ. (a and c) For total lysates WT and mutant MCT8 expression levels are expressed as MCT8/GADPH ratio relative to WT MCT8 (100%) and presented as mean 6 standard error of the mean (SEM) of two to three independent experiments. WT and mutant MCT8 cell surface expression levels in COS-1 cells are expressed as MCT8 (surface)/GADPH (input) ratio relative to WT MCT8 (100%) and presented as mean 6 SEM of two independent experiments. T3 (dark gray) and T4 (light gray) uptake by COS-1 (d) and JEG-3 (e) cells transiently cotransfected with WT or indicated mutant MCT8 and CRYM in 5 minutes at 37°C. All uptake values are corrected for background TH uptake levels observed in COS-1 or accessible residues Cys481, Cys497, and His192, we here identified Arg271 and Arg445 as accessible targets for PG modification. Given the partial protective effect of substrate, at least one of these residues should be exposed at the substrate pore. Indeed, our outward-open model predicts Arg445 at the substrate-binding center and molecular dynamic simulations even suggested a direct interaction with the carboxyl group of T3. Although the importance of the Arg445 residue has been previously illustrated by the deleterious effects of the R445C mutation, found in a patient with AHDS, and the experimental R445A mutation (10, 39), we here provided in vitro evidence that may support the involvement of Arg445 in direct substrate interactions. Interestingly, iodothyronamines, which lack the carboxyl group, are not substrates for MCT8 (4) . Together, this suggests that the interaction between the negatively charged carboxyl group of TH and the positively charged guanidine-group of Arg445 is an important determinant in substrate recognition. Of interest, Arg601 at the substrate-binding center of the T4 transporter Organic Anion Transporter Protein 1C1 is also crucial for interaction with the carboxyl group of T4, suggesting that TH transporters may share common features in their substrate interaction mechanism (40) . Moreover, our model provides insights into how this interaction may induce conformational changes of the MCT8 protein upon substrate binding. Although molecular dynamic simulations should be interpreted with caution if performed on protein structure models, a hydrogen bond or electrostatic interaction between Arg445 (TMD8) and Asp498 (TMD10) is observed, in line with our previous in vitro data (10) . Alterations of this interaction in the presence of substrate change the orientation of the Asp498 side-chain and hence TMD10, which may contribute to the substrate-induced conformational changes. The negatively charged carboxyl group of TH may thus compete with Asp498 for hydrogen bond formation with Arg445. The importance of the negatively charged Asp498 residue is illustrated by the deleterious effect of the D498N patient mutation and the artificial D498A mutation, whereas the artificial D498E mutant retains full activity (10, 41) . Although we have previously shown that the charge exchange double mutant R445D+D498R retained partial transporter activity, this is strongly reduced compared with WT MCT8 (10) . Despite the preservation of the putative salt-bridge in this double mutant that may partly account for its higher residual transporter activity compared with the corresponding single mutants, the charge distribution and hence the structure of the binding pocket is likely to be altered. We speculate that due to the incorrect orientation of the charged side-chains, the efficiency by which the salt-bridge is disturbed by the substrate molecule is reduced, resulting in the observed decreased transporter activity.
The other PG target, Arg271, is predicted at the extracellular end of TMD4, permitting PG modification from the extracellular environment. Although a direct interaction with substrate is not likely regarding its position, alterations in the local structure may be detrimental for MCT8 function, as is illustrated by the identification of the R271H mutation in a patient with AHDS (42) . Given the mild effect of the Ala substitution, the positive charge of Arg271 is not likely to be crucial for the maintenance of structural integrity. Indeed, a Leu is located at the corresponding position in MCT10, an efficient T3 transporter (18) .
In line with previous in vitro studies, His192 was found to interact with the phenolic hydroxyl group of TH at the putative substrate-binding center (11) . Of note, also the corresponding residue in GlpT (Arg45) is suggested to directly interact with substrate (43, 44) , whereas the corresponding residue in FucP (Asn45) is clearly accessible from the substrate pore (35) . Interestingly, the neighboring Asp46 in FucP residue has been suggested to directly interact with substrate and its Table 6 .
substitution by an Asn or Ala completely abrogated transport function (35) . Based on the MCT8 homology model in the inward-open conformation, it was postulated that His192 and Arg445 could form a His-Arg clamp to dock TH at the substrate-binding center (4, 10) . Also in the outward-open conformation, a TH molecule could be docked between both residues, suggesting a similar substrate docking mechanism in both conformations, which is not uncommon for MFS transporters (43) . Interestingly, despite its clear susceptibility for DEPC, the substitution of His192 by Ala has only minor effects on TH transport (11, 45) , which suggests an important role for other residues in substrate docking. In addition, it should be noted that FucP contains a proline-kink in TMD1 one turn above the Asp46 residue resulting in an irregular a-helical backbone pattern. Because this Pro is not preserved in MCT8, prediction of the exact orientation of amino acid side-chains in TMD1 may be less accurate.
Although the inward-open model predicted a second His-Arg clamp involving His415 and Arg301, this is not observed in our current outward-open model in which His415 (extracellular end of TMD7) and Arg301 (intracellular end of TMD5) are located at distant sites (45) . Especially the location of His415 differs from previous studies where it was predicted to be positioned close to the substrate-binding center in the middle of TMD7. However, the abundance of charged residues in close proximity of His415 (Lys418-Glu429), which are preferably located outside the cell membrane, pull His415 toward the extracellular end of TMD7 in our current structural alignment. Importantly, this localization is supported by our previous studies suggesting that the inhibitory effect of the His-specific reagent DEPC is solely mediated through modification of His192 (11) . This implies that all other His residues (including His415) are located at inaccessible positions, or at positions where modification by DEPC does not interfere with substrate passage. Nevertheless, in vitro studies have suggested that different His415 substitutions affect substrate interactions (45) . Further studies are required to elucidate the exact functional role of His415 during substrate translocation.
In addition, we showed that the Ala substitutions of Phe189, Met227, Phe279, Gly282, Phe287, and Phe501, all found within 5Å from the substrate molecule at the substrate-binding center, results in varying reductions in apparent Vmax. Moreover, M227A, F279A, F287A, and F501A induce a decrease in apparent Km, suggesting an altered mode of substrate binding. These findings strengthen the current localization of these residues in our model. We speculate that the impact of their Ala substitution on T3 transport kinetics is related to the predicted orientation of the side-chains of these residues toward the substrate molecule.
The bulky side-chain of Phe287 forms the bottom of the putative substrate-binding center, and predominantly faces the b-methylene group of the iodothyronine substrate. We speculate that shortening of the Phe287 side chain may result in narrowing of the substrate-binding center, limiting the space for the substrate molecule. This could explain the greater impact of the F287A substitution on the transport of the larger substrate molecule T4, compared with T3. Alternatively, shortening of its side-chain may have unfavorable effects on the orientation of the carboxyl group of the substrate toward the Arg445 residue. Interestingly, recent studies suggested that substitution of the corresponding residue in MCT10 (Tyr184) with Phe allows T4 transport by MCT10, supporting our hypothesis that the amino acid side-chain at this position is important for substrate docking and selection (46) .
The aromatic side chain of Phe279 parallels the side chain of His192, which together with Gly282 and Phe189 form a cavity in which the phenolic ring of TH perfectly fits. We speculate that Phe279 and His192 prevent the rotation of the iodothyronine phenolic ring in the substrate pore. Shortening of the Phe279 sidechain to an Ala may increase substrate mobility and thereby alter transporter kinetics. Importantly, the F279A mutation clearly decreased cell surface expression, which indicates that a bulky side-chain at this position may be important for protein integrity. Although Phe189 and Gly282 both form the bottom of the cavity, Phe189 also faces part of the iodothyronine tyrosyl ring and likely modulates the angle between the two aromatic rings in TH. In addition to the larger change in side-chain volume in case of a Phe to Ala substitution, this may partly explain the greater impact of F189A compared with G282A. The observed reduction in Vmax of the G282A substituent appeared to be predominantly caused by a reduction in total MCT8 protein and cell surface expression levels, rather than interference with substrate translocation. Although it would have been of interest to study the impact of the introduction of larger residues at this position, further side-chain elongation to a Cys already severely affects protein stability and subcellular localization, hampering the assessment of its impact on substrate translocation efficiency (13) . Of note, Tyr34 in MCT1, corresponding to Phe189 in MCT8, was recently suggested to directly interact with its inhibitor AR-C155858, supporting our current findings (47) .
The M227A and F501A mutants only moderately affect T3 transport kinetics, suggesting that these residues do not interact importantly with the substrate. Met227 is predicted to face the ether bond and one of the iodine substituents in the tyrosyl ring of the T3 molecule. Both 3,3 0 ,5 0 -triiodo-L-thyronine (rT3) and 3,3 0 -diiodo-L-thyronine, which have only one iodine substituent in this ring, are suitable substrates for MCT8. This indicates that double substitution of the inner ring is not required for iodothyronine transport by MCT8. Phe501 predominantly faces the b-methylene group of the alanine side-chain of T3 from the side. Because the carboxyl group already firmly interacts with the Arg445, located in close structural proximity, the relative contribution of Phe501 may be less important. It is not excluded that the bulky side-chains of the Met227 and Phe501 residues have a role in determining substrate specificity by excluding larger substrates.
The strength of our model is that it accommodates all currently available in vitro results from chemical modification studies. Moreover, any alternative alignment of especially TMD1, TMD4, TMD8, and TMD10, together constituting the major part of the substrate-binding center, would conflict with these in vitro findings, re-enforcing the accuracy of our current outward-open model. In contrast, strong structural clues for several other TMDs (e.g., TMDs 3, 6, 9, and 12) are currently lacking. Given their expected structural organization, these domains are likely to be inaccessible for chemical modification, warranting different experimental approaches to validate their structural organization. Characterization of missense mutations encountered in patients who have AHDS and the substitution of the affected residue by an Ala or a residue that shares specific functional or structural characteristics with the original residue could help to define which functional and structural properties of the native residue are required for optimal MCT8 function. This may help to further validate and optimize the predicted structure of these inaccessible domains. Although our current model explains many of the available in vitro data, this may also be the case for other models based on different templates or targettemplate alignments. In the end, discrepancies between the existing models (e.g., the position of His415) will be resolved only when crystal structures of MCT8 or one of its MCT family members have been elucidated. Additionally, the crystallization of other MFS members with higher sequence similarity to MCT8 than FucP (29.5%) would offer more suitable templates for structural modeling. We also emphasize that details on amino acid side-chain orientation should be considered with some reservation, especially in those parts of the model at which the predicted secondary structure of MCT8 differs from that of the template (e.g., TMD1). In this respect, it should also be noted that the relatively low resolution of the FucP template crystal (3.2Å) may already hamper correct prediction of amino acid side-chains due to uncertainties in the template structure itself.
Taken together, we here report a structural model of MCT8 in outward-open conformation, providing insights into MCT8 structure and function. Our model improves our understanding of the recognition and binding of extracellular substrate. We demonstrate that our model can be used as a complementary tool in the analysis of the pathogenic mechanism of several previously reported missense mutations, identified in patients who have AHDS. Further refinement will also allow its use for in silico prediction of the pathogenicity of newly identified mutations and screens for putative novel MCT8 substrates and inhibitors.
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